Skip to main content

849-010 A Randomized PHase 3 Study of MRTX849 in Combination with Cetuximab Versus Chemotherapy in Patients with Advanced Colorectal Cancer with KRAS G12C Mutation with Disease Progression On or After Standard First-Line Therapy

NCT04793958

A Randomized PHase 3 Study of MRTX849 in Combination with Cetuximab Versus Chemotherapy in Patients with Advanced Colorectal Cancer with KRAS G12C Mutation with Disease Progression On or After Standard First-Line Therapy

Associated Conditions

Colorectal Cancer

Principal Investigator

Mohamedtaki Tejani

Sponsor

Mirati Therapeutics

This is a study involving an investigational (experimental) drug called MRTX849, being developed by Mirati Therapeutics, Inc., which is the company that provides MRTX849 study drug and is funding and organizing the study. Investigational means that MRTX849 has not been proven to help people with colorectal cancer and is not approved by regulatory authorities such as the United States Food and Drug Administration (US FDA). This study will evaluate the effectiveness of the combination of MRTX849 with cetuximab in subjects with colorectal cancer who are experiencing progression on or after first-line chemotherapy.

This study is currently enrolling.